International Journal of Molecular and Cellular Medicine (IJMCM)
Babol University of Medical Sciences
Mon, Jun 9, 2025
[Archive]
Volume 3, Issue 4 (Int J Mol Cell Med 2014)
Int J Mol Cell Med 2014, 3(4): 207-215 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Naderi M, Gholipour N, Zolfaghari M R, Maryam Moradi B, Moghadam A Y, Gholamreza M. Hepatitis C Virus and Vaccine Development. Int J Mol Cell Med 2014; 3 (4) :207-215
URL: http://ijmcmed.org/article-1-173-en.html
URL: http://ijmcmed.org/article-1-173-en.html
Malihe Naderi1 
, Naghmeh Gholipour2 , Mohammad Reza Zolfaghari3 , Binabaj Maryam Moradi4 , Ahmad Yegane Moghadam5 , Motalleb Gholamreza6
, Naghmeh Gholipour2 , Mohammad Reza Zolfaghari3 , Binabaj Maryam Moradi4 , Ahmad Yegane Moghadam5 , Motalleb Gholamreza6
1- Department of Microbiology, Qom branch, Islamic Azad University, Qom, Iran. , rezamotalleb@gmail.com
2- National Institute of Genetic Engineering and Biotechnology, Department of Molecular Genetics, Tehran, Iran.
3- Department of Microbiology, Qom branch, Islamic Azad University, Qom, Iran.
4- Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran.
5- Kashan University of Medical Sciences, Department of Otolaryngology, Kashan, Iran.
6- Faculty of Science, Department of Biology, University of Zabol, Zabol, Iran.
2- National Institute of Genetic Engineering and Biotechnology, Department of Molecular Genetics, Tehran, Iran.
3- Department of Microbiology, Qom branch, Islamic Azad University, Qom, Iran.
4- Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran.
5- Kashan University of Medical Sciences, Department of Otolaryngology, Kashan, Iran.
6- Faculty of Science, Department of Biology, University of Zabol, Zabol, Iran.
Abstract: (10979 Views)
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine.
Type of Study: Original Article |
Subject:
Infectious disease (Molecular and Cellular aspects)
Received: 2014/05/23 | Accepted: 2014/08/2 | Published: 2014/09/10
Received: 2014/05/23 | Accepted: 2014/08/2 | Published: 2014/09/10
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
